Clinical trial conducted in Greece
The General University Hospital of Ioannina has conducted an independent clinical study evaluating the performance of Calmark Neo-Bilirubin against laboratory analysis and comparing results from venous and capillary blood. All 85 patients are included in the study, the result will now be compiled and published.
The General University Hospital of Ioannina was founded in 1990 with a capacity of 800 beds. University Hospital of Ioannina is an academic medical center which shares its affiliation with Ioannina University’s School of Medicine and the Ioannina School of Nursing. There are nearly 45,000 people treated annually in the Hospitals Care Clinics and almost 130,000 people use Hospitals Casualty Department every year. University Hospital of Ioannina offers a wide variety of facilities such as, surgical procedures, including transplantations, laparoscopic techniques.
The clinical study is performed at the Neonatal Clinic (NICU) within School of Health Sciences, Faculty of Medicine, Children Health Department. This department performs remarkable teaching and research work in Pediatrics and Neonatology. The study is led by Vasileios Giapros, Professor of Pediatrics & Neonatology & Head of Neonatal Department.
"This is an important milestone for Calmark that will enable us to address questions about capillary sampling from, for example, the heel of the child," says Camilla Arneving, Acting CEO of Calmark. "Since the healthcare system in Sweden nowadays avoids capillary blood tests from newborns, we have not been able to investigate this in our clinical studies at Södersjukhuset. However, capillary sampling is common in the rest of the world, and thus, it is important for us to be able to provide it.”
"We are very pleased to help facilitate this important, one-of-a-kind study examining the difference between venous blood and capillary blood in newborns," says Marios Pappas, Sales and Marketing Director at Calmark's distributor in Greece, Prime Biosciences. "Even so, the venous sample is also analyzed in the hospital's biochemical laboratory on a Beckman Coulter instrument. We look forward to sharing the results when the study has been published."
Every care has been taken in the translation of this document. In the event of discrepancies, the Swedish original will supersede the English translation.
For more information about Calmark Sweden AB, please contact:
Camilla Arneving, Acting CEO
Telefon: +46 (0)10 204 01 50
E-post: camilla.arneving@calmark.se
www.calmark.se
Calmark Sweden AB is a medical technology company that manufactures and markets a point-of-care (POC) analysis method with easier and faster diagnostics of medical conditions in newborns. The unique test platform consists of a portable instrument and test cassettes for various biomarkers. The first test, Neo-Bilirubin, is CE marked and measures the bilirubin level in whole blood for jaundice detection in newborns. In the Western world, the introduction of POC diagnostics is resulting in huge savings and shorter care chains. In less developed healthcare systems, the product offers a decision support which is currently lacking, since the access to hospital laboratories often is limited. Calmark aims to become the global leader in POC diagnostics for newborns and, in the long term, to offer all relevant tests for the first period of life. The B share is listed on the Spotlight Stock Market and is traded under the CALMA B ticker. Read more at www.calmark.se/eng/home.
Tags: